Recent Developments in WOMEN'S HEALTH DIAGNOSTICS Market

• In 2021, F. Hoffmann-La Roche Ltd. Launched the uPath HER2 (4B5) Image Analysis and uPath Dual ISH Image Analysis.
• In 2021, Hologic, Inc. acquired Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, to strengthen its presence in the women’s health diagnostics market.

According to a research report "Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025" The global women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.
Get Informational PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901
Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe
Quest Diagnostics Incorporated (US), Hologic, Inc. (US), Abbott Laboratories (US), Siemens AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), General Electric Company (US), and Becton, Dickinson and Company (US).
The prenatal genetic screening & carrier testing segment is expected to grow at the highest CAGR during the forecast period
The prenatal genetic screening & carrier testing segment is projected to witness the highest growth in the women’s health diagnostics market during the forecast periods (2020-2025). Growth in this segment is driven mostly by the adverse effects of Down’s syndrome, Edwards’ syndrome, CF, and TORCH infections in infants, and increasing awareness among women regarding prenatal screening for these disorders.
The hospitals & clinics segment is expected to account for the largest share of the women’s health diagnostics market
The large share of this segment can be attributed to a greater proportion of patients (women) visiting hospitals to diagnose/treat health issues. Other factors such as growing consolidation among hospitals and the implementation of ACOs in the US are also expected to support the growth of this end-user segment in the coming years.
Asia Pacific is expected to account for the highest CAGR for players operating in the women’s health diagnostics market
The Asia Pacific women’s health diagnostics market is expected to grow at the highest CAGR from 2020 to 2025. Improving healthcare infrastructures, growing per capita incomes, and the rising focus of key market companies in this region are major factors driving the growth of the APAC women’s health diagnostics market.
Request for Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901
Recent Developments in WOMEN'S HEALTH DIAGNOSTICS Market • In 2021, F. Hoffmann-La Roche Ltd. Launched the uPath HER2 (4B5) Image Analysis and uPath Dual ISH Image Analysis. • In 2021, Hologic, Inc. acquired Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, to strengthen its presence in the women’s health diagnostics market. According to a research report "Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025" The global women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period. Get Informational PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901 Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe Quest Diagnostics Incorporated (US), Hologic, Inc. (US), Abbott Laboratories (US), Siemens AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), General Electric Company (US), and Becton, Dickinson and Company (US). The prenatal genetic screening & carrier testing segment is expected to grow at the highest CAGR during the forecast period The prenatal genetic screening & carrier testing segment is projected to witness the highest growth in the women’s health diagnostics market during the forecast periods (2020-2025). Growth in this segment is driven mostly by the adverse effects of Down’s syndrome, Edwards’ syndrome, CF, and TORCH infections in infants, and increasing awareness among women regarding prenatal screening for these disorders. The hospitals & clinics segment is expected to account for the largest share of the women’s health diagnostics market The large share of this segment can be attributed to a greater proportion of patients (women) visiting hospitals to diagnose/treat health issues. Other factors such as growing consolidation among hospitals and the implementation of ACOs in the US are also expected to support the growth of this end-user segment in the coming years. Asia Pacific is expected to account for the highest CAGR for players operating in the women’s health diagnostics market The Asia Pacific women’s health diagnostics market is expected to grow at the highest CAGR from 2020 to 2025. Improving healthcare infrastructures, growing per capita incomes, and the rising focus of key market companies in this region are major factors driving the growth of the APAC women’s health diagnostics market. Request for Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901
12
0 Comments 0 Shares
Sponsored